NCT00620555

A Phase III Open-Label Extension Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With Partial Seizures

A 52 Weeks, Open-Label, Multicenter Study Evaluating The Efficacy And Safety Of Gabapentin As Adjunctive Therapy In Pediatric Patients Who Have Completed The 12 Weeks Treatment In Study A9451162 (NCT00603473)

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 65 (actual)
• Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
• Sex: All
• Age: 3 Years
• Healthy volunteers: Not accepted

Summary

Examine the safety and efficacy of gabapentin as adjunctive therapy in Japanese pediatric patients with partial seizures

Conditions

• Epilepsies, Partial

Interventions

Type	Name	Description
DRUG	gabapentin	Orally administered gabapentin

Timeline

• Start date: 2008-05-01
• Primary completion: 2010-12-01
• Completion: 2010-12-01
• First posted: 2008-02-21
• Last updated: 2021-02-03
• Results posted: 2011-12-20

Locations

22 sites across 1 country: Japan